Clinical Trial

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-09-07; most recent amendment 2024-06-21.
Trial Details
NCT Number NCT05532696
Lead Sponsor Anbogen Therapeutics, Inc.
Conditions Advanced Solid Tumor, Non Small Cell Lung Cancer, HER2 Mutations
Enrollment 61 participants
Start Date 2022-09-27
Primary Completion 2026-11 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2024-06-24